Protocol Ledger

NCT05997602 · Phase II · RECRUITING

To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH

Interventional Phase II clinical trial protocol NCT05997602 sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-09-28 Enrollment: 56 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05997602
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)56 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05997602
Protocol FieldVerified Registry Value
NCT IdentifierNCT05997602
Consolidated Lead SponsorShanghai Fosun Pharmaceutical Industrial Development Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment56 participants (ESTIMATED)
Registered Start Date2023-09-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05997602
Hospital Research SiteLocationSite Profile
Beijing Children's Hospital, Capital Medical UniversityBeijing, ChinaOpen Hospital Dossier ->
The First Affiliated Hospital, Sun-Yat Sen UniversityGuangzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI